
About QMS MAS
QMS MAS is a publicly listed company based in Mumbai (India) founded in 1994. Provider of digital marketing scientific solution services for medical devices manufacturers. The company has 83 employees. QMS MAS has completed 1 acquisition, including Saarathi Healthcare. Its Indian entity Qms Medical Allied Services Limited reported revenue of ₹174 Cr. Its focus areas include Medical Device Outsourcing.
Company details
QMS MAS was founded in 1994 and is located in Mumbai, India. Digital marketing and scientific solution services are offered by the company to manufacturers in the medical devices sector. Operations are centered on supporting these clients with specialized tools and strategies for market outreach and technical compliance. The focus remains on the healthcare industry, with services tailored to regional and global needs in device production.
- Headquarters Mumbai, India
- Employees 83
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website qmsmas.com
- Social LinkedIn X Facebook
- Legal Name Qms Medical Allied Services Limited
- Market Cap₹329 Cr
QMSMEDI-BE · NSE
- Share Price₹170.01
+0.05% today
- Revenue₹173 Cr
FY 2025-26 · +10.8% YoY
- EBITDA₹26.62 Cr
Margin 15.4%
- Net Profit₹10.07 Cr
FY 2025-26 · -16.6% YoY
- P/E (TTM)33.3x
P/B 3.7x
- ROE12.3%
ROCE 13.9%
- Debt / Equity0.69
Interest cover 29.9x
- Employee Count83
- Investments & Acquisitions
Associated legal entities of QMS MAS
QMS MAS operates through Qms Medical Allied Services Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Qms Medical Allied Services Limited Listed CIN L33309MH2017PLC299748 | Active | 14 Sep 2017 | Mumbai, Maharashtra | ₹174 Cr | 83 | 8 | View details |
Board of directors of Qms Medical Allied Services Limited (QMS MAS)
Qms Medical Allied Services Limited is the primary company behind QMS MAS. The board of Qms Medical Allied Services Limited currently have 6 directors; the longest-serving is Mahesh Pahalraj Makhija, appointed in 2017. 10 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Mahesh Pahalraj Makhija DIN 02700606 | Managing Director | 14 Sep 2017 | 9 yrs 2 mo | Qms Medical Allied Services Limited |
| Niken Ravin Shah DIN 07604022 | Director | 11 Mar 2022 | 4 yrs 8 mo | Qms Medical Allied Services Limited |
| Prajwal Jayasheela Poojari DIN 07480513 | Director | 15 Jun 2022 | 4 yrs 5 mo | Qms Medical Allied Services Limited |
| Deena Nath Pathak DIN 02104727 | Director | 23 Aug 2024 | 2 yrs 2 mo | Qms Medical Allied Services Limited |
| Sarita Vijay Mahajan DIN 10841279 | Director | 19 Nov 2024 | 1 yr 11 mo | Qms Medical Allied Services Limited |
| Pranav Manhar Badheka DIN 06460764 | Director | 03 Sep 2026 | 2 mo | Qms Medical Allied Services Limited |
IPO & Listings of QMS MAS
QMS MAS is a publicly listed company on the NSE with ticker symbol QMSMEDI in India, operating in the Distribution services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Oct 2022
- Listed onNSE: QMSMEDI
- Listed entityQMS Medical Allied Services Limited
- Exchange sectorDistribution services
- ISININE0FMW01018
- Share price₹180.05 (+0.66% on the day) · 2026-10-14
- Market capitalisation₹356 Cr
- Price to earnings31.4
- EPS (diluted, trailing year)₹5.73
- Dividend yield0.27%
- Volume (last session)13,570
Financials of QMS MAS
Exchange-reported figures of Qms Medical Allied Services Limited, the listed company behind QMS MAS (NSE: QMSMEDI-BE).
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 173 | 156 | 122 |
| Revenue growth | +10.8% | +27.7% | - |
| EBITDA | 26.62 | 25.40 | 18.34 |
| EBITDA margin | +15.4% | +16.3% | +15.0% |
| Profit before tax | 16.38 | 18.65 | 12.23 |
| Net profit | 10.07 | 12.07 | 9.00 |
| Net profit margin | +5.8% | +7.7% | +7.4% |
| EPS (₹) | 6.32 | 6.77 | 5.04 |
| Balance sheet | |||
| Total assets | 189 | 168 | 113 |
| Net worth | 104 | 89.71 | 78.51 |
| Total debt | 74.48 | 60.28 | 34.54 |
| Cash & bank | 1.20 | 1.07 | 0.31 |
| Net working capital | 113 | 94.52 | 81.88 |
| Cash flow | |||
| Cash from operations | 19.44 | 19.17 | 1.36 |
| Cash from investing | (20.42) | (45.49) | (2.73) |
| Cash from financing | 1.11 | 26.84 | 0.41 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 52.52 | 56.87 | 44.42 | 37.26 | 44.70 | 46.50 | 44.58 | 43.87 |
| Revenue growth (YoY) | +17.5% | +22.3% | -0.4% | -15.1% | +20.2% | +53.1% | - | - |
| Other income | 0.22 | 0.42 | 0.22 | 0.30 | 0.22 | 0.32 | 1.09 | 0.19 |
| EBITDA | 6.52 | 8.31 | 5.91 | 6.75 | 6.92 | 6.54 | 6.37 | 6.95 |
| EBITDA margin | +12.4% | +14.6% | +13.3% | +18.1% | +15.5% | +14.1% | +14.3% | +15.8% |
| Depreciation | 1.60 | 1.47 | 1.39 | 1.02 | 0.94 | 0.93 | 1.36 | 0.86 |
| Interest | 1.86 | 1.71 | 2.08 | 1.75 | 1.36 | 1.44 | 1.41 | 1.31 |
| Profit before tax | 3.28 | 5.55 | 2.66 | 4.28 | 4.84 | 4.49 | 4.69 | 4.97 |
| Tax | 0.84 | 1.59 | 0.78 | 1.10 | 1.27 | 1.33 | 1.09 | 1.50 |
| Net profit | 2.44 | 3.96 | 1.88 | 3.18 | 3.57 | 3.16 | 3.60 | 3.47 |
| EPS (₹) | 1.26 | 2.05 | 0.97 | 1.24 | 1.71 | 2.20 | 1.87 | 1.63 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 152 | 145 | 122 | 104 | 146 | 122 | 72.74 |
| Revenue growth | +5.1% | +18.6% | +17.4% | -28.9% | +19.9% | +67.8% | - |
| EBITDA | 21.08 | 23.33 | 18.34 | 11.33 | 16.64 | 16.99 | 9.60 |
| EBITDA margin | +13.8% | +16.1% | +15.0% | +10.9% | +11.4% | +13.9% | +13.2% |
| Profit before tax | 9.31 | 14.43 | 12.23 | 8.71 | 14.46 | 14.90 | 8.72 |
| Net profit | 6.59 | 10.42 | 9.00 | 6.38 | 9.69 | 10.91 | 6.32 |
| Net profit margin | +4.3% | +7.2% | +7.4% | +6.1% | +6.6% | +8.9% | +8.7% |
| EPS (₹) | 3.51 | 5.84 | 5.04 | 3.57 | 28.40 | 29.02 | 21.00 |
| Balance sheet | |||||||
| Total assets | 196 | 166 | 113 | 96.01 | 63.01 | 39.93 | 21.01 |
| Net worth | 104 | 88.04 | 78.51 | 70.40 | 31.03 | 20.32 | 9.41 |
| Total debt | 90.92 | 77.25 | 2.37 | 25.52 | 31.97 | 19.60 | 11.60 |
| Cash & bank | 0.11 | 0.39 | 0.31 | 2.37 | 2.16 | 1.38 | 0.66 |
| Net working capital | 103 | 88.08 | 81.88 | 65.60 | 54.85 | 29.40 | 17.58 |
| Cash flow | |||||||
| Cash from operations | 18.77 | 26.09 | 1.36 | (7.54) | (1.72) | 1.88 | 4.18 |
| Cash from investing | (18.27) | (48.90) | (1.78) | (25.10) | 2.37 | (7.84) | (3.66) |
| Cash from financing | (0.78) | 22.88 | (1.07) | 31.74 | 0.13 | 6.69 | 0.00 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.94 | 52.34 | 39.19 | 29.54 | 41.25 | 42.32 | 42.38 | 39.38 |
| Revenue growth (YoY) | +23.5% | +23.7% | -7.5% | -25.0% | +26.0% | +39.4% | - | - |
| Other income | 0.08 | 0.25 | 0.07 | 0.13 | 0.00 | 0.15 | 0.13 | 0.12 |
| Total expenses | 44.65 | 45.34 | 34.81 | 25.77 | 35.12 | 35.99 | 34.56 | 34.05 |
| EBITDA | 6.29 | 7.00 | 4.38 | 3.77 | 6.13 | 6.33 | 7.82 | 5.33 |
| EBITDA margin | +12.3% | +13.4% | +11.2% | +12.8% | +14.9% | +15.0% | +18.5% | +13.5% |
| Depreciation | 1.43 | 1.31 | 1.22 | 0.92 | 0.83 | 0.83 | 0.90 | 0.91 |
| Interest | 2.21 | 2.05 | 2.38 | 2.06 | 1.73 | 1.77 | 2.73 | 1.31 |
| Profit before tax | 2.73 | 3.89 | 0.85 | 0.92 | 3.57 | 3.88 | 4.32 | 3.23 |
| Tax | 0.69 | 1.22 | 0.24 | 0.34 | 0.93 | 1.20 | 1.26 | 0.89 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 52.52 | 56.87 | 44.42 | 37.26 | 44.70 | 46.50 | 44.58 | 43.87 |
| Revenue growth (YoY) | +17.5% | +22.3% | -0.4% | -15.1% | +20.2% | +53.1% | - | - |
| Other income | 0.22 | 0.42 | 0.22 | 0.30 | 0.22 | 0.32 | 1.09 | 0.19 |
| EBITDA | 6.52 | 8.31 | 5.91 | 6.75 | 6.92 | 6.54 | 6.37 | 6.95 |
| EBITDA margin | +12.4% | +14.6% | +13.3% | +18.1% | +15.5% | +14.1% | +14.3% | +15.8% |
| Depreciation | 1.60 | 1.47 | 1.39 | 1.02 | 0.94 | 0.93 | 1.36 | 0.86 |
| Interest | 1.86 | 1.71 | 2.08 | 1.75 | 1.36 | 1.44 | 1.41 | 1.31 |
| Profit before tax | 3.28 | 5.55 | 2.66 | 4.28 | 4.84 | 4.49 | 4.69 | 4.97 |
| Tax | 0.84 | 1.59 | 0.78 | 1.10 | 1.27 | 1.33 | 1.09 | 1.50 |
| Net profit | 2.44 | 3.96 | 1.88 | 3.18 | 3.57 | 3.16 | 3.60 | 3.47 |
| EPS (₹) | 1.26 | 2.05 | 0.97 | 1.24 | 1.71 | 2.20 | 1.87 | 1.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 173 | 156 | 122 |
| Revenue growth | +10.8% | +27.7% | - |
| Other income | 1.06 | 1.72 | 0.46 |
| Total expenses | 146 | 131 | 104 |
| Employee cost | 0.00 | 7.54 | 3.67 |
| EBITDA | 26.62 | 25.40 | 18.34 |
| EBITDA margin | +15.4% | +16.3% | +15.0% |
| Depreciation | 4.61 | 3.83 | 3.44 |
| Interest | 6.69 | 4.64 | 3.13 |
| Profit before tax | 16.38 | 18.65 | 12.23 |
| Tax | 4.51 | 4.96 | 3.23 |
| Net profit | 10.07 | 12.07 | 9.00 |
| Net profit margin | +5.8% | +7.7% | +7.4% |
| EPS (₹) | 6.32 | 6.77 | 5.04 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 19.34 | 17.85 | 17.85 |
| Reserves & surplus | 84.86 | 71.86 | 60.66 |
| Shareholders' funds (net worth) | 104 | 89.71 | 78.51 |
| Minority interest | 9.77 | 17.39 | 0.00 |
| Secured loans | 69.01 | 54.82 | 33.46 |
| Unsecured loans | 5.47 | 5.46 | 1.08 |
| Total debt | 74.48 | 60.28 | 34.54 |
| Total liabilities | 189 | 168 | 113 |
| Assets | |||
| Gross block | 72.25 | 66.21 | 30.03 |
| Net block | 54.62 | 52.42 | 23.58 |
| Capital work in progress | 2.83 | 3.19 | 2.06 |
| Investments | 5.46 | 3.23 | 2.11 |
| Inventories | 45.92 | 39.33 | 37.58 |
| Sundry debtors | 67.32 | 57.93 | 41.39 |
| Cash & bank balances | 1.20 | 1.07 | 0.31 |
| Loans & advances | 22.12 | 18.48 | 24.39 |
| Total current assets | 137 | 117 | 104 |
| Total current liabilities | 23.75 | 22.29 | 21.79 |
| Net working capital | 113 | 94.52 | 81.88 |
| Total assets | 189 | 168 | 113 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 1.06 | 0.31 | 1.27 |
| Net cash from operating activities | 19.44 | 19.17 | 1.36 |
| Net cash from investing activities | (20.42) | (45.49) | (2.73) |
| Net cash from financing activities | 1.11 | 26.84 | 0.41 |
| Net change in cash | 0.13 | 0.52 | (0.96) |
| Closing cash | 1.20 | 1.07 | 0.31 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +10.8% | +27.7% | - |
| EBITDA growth | +4.8% | +38.5% | - |
| PBT growth | -11.9% | +52.6% | +9997.0% |
| Net income growth | -16.6% | +34.1% | - |
| Profitability & leverage | |||
| Net income margin | +6.9% | +8.8% | +7.4% |
| Return on capital employed | +14.0% | +17.7% | +13.6% |
| Return on net worth | +12.3% | +16.3% | +11.5% |
| Debt / equity | 0.69 | 0.56 | 0.44 |
| Long-term debt / equity | 0.08 | 0.07 | 0.03 |
| Interest cover | 29.85 | 21.50 | 21.01 |
| Efficiency & per share | |||
| Fixed asset turnover | 2.50 | 3.24 | 4.07 |
| Inventory turnover | 4.06 | 4.06 | 3.25 |
| Debtors turnover | 2.76 | 3.14 | 2.95 |
| EPS (₹) | 5.24 | 6.77 | 5.04 |
| Dividend per share (₹) | 0.50 | 0.50 | 0.00 |
| Book value per share (₹) | 53.88 | 50.26 | 43.99 |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 50.94 | 52.34 | 39.19 | 29.54 | 41.25 | 42.32 | 42.38 | 39.38 |
| Revenue growth (YoY) | +23.5% | +23.7% | -7.5% | -25.0% | +26.0% | +39.4% | - | - |
| Other income | 0.08 | 0.25 | 0.07 | 0.13 | 0.00 | 0.15 | 0.13 | 0.12 |
| Total expenses | 44.65 | 45.34 | 34.81 | 25.77 | 35.12 | 35.99 | 34.56 | 34.05 |
| EBITDA | 6.29 | 7.00 | 4.38 | 3.77 | 6.13 | 6.33 | 7.82 | 5.33 |
| EBITDA margin | +12.3% | +13.4% | +11.2% | +12.8% | +14.9% | +15.0% | +18.5% | +13.5% |
| Depreciation | 1.43 | 1.31 | 1.22 | 0.92 | 0.83 | 0.83 | 0.90 | 0.91 |
| Interest | 2.21 | 2.05 | 2.38 | 2.06 | 1.73 | 1.77 | 2.73 | 1.31 |
| Profit before tax | 2.73 | 3.89 | 0.85 | 0.92 | 3.57 | 3.88 | 4.32 | 3.23 |
| Tax | 0.69 | 1.22 | 0.24 | 0.34 | 0.93 | 1.20 | 1.26 | 0.89 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 152 | 145 | 122 | 104 | 146 | 122 | 72.74 |
| Revenue growth | +5.1% | +18.6% | +17.4% | -28.9% | +19.9% | +67.8% | - |
| Other income | 0.36 | 0.46 | 0.46 | 0.74 | 1.42 | 0.06 | 0.04 |
| Total expenses | 131 | 122 | 104 | 92.71 | 130 | 105 | 63.14 |
| Employee cost | 0.00 | 6.00 | 3.67 | 2.61 | 3.83 | 1.56 | 0.92 |
| EBITDA | 21.08 | 23.33 | 18.34 | 11.33 | 16.64 | 16.99 | 9.60 |
| EBITDA margin | +13.8% | +16.1% | +15.0% | +10.9% | +11.4% | +13.9% | +13.2% |
| Depreciation | 4.12 | 3.40 | 3.44 | 1.07 | 1.16 | 0.74 | 0.36 |
| Interest | 8.01 | 5.96 | 3.13 | 2.29 | 2.44 | 1.41 | 0.56 |
| Profit before tax | 9.31 | 14.43 | 12.23 | 8.71 | 14.46 | 14.90 | 8.72 |
| Tax | 2.72 | 4.00 | 3.23 | 2.33 | 3.77 | 3.99 | 2.40 |
| Net profit | 6.59 | 10.42 | 9.00 | 6.38 | 9.69 | 10.91 | 6.32 |
| Net profit margin | +4.3% | +7.2% | +7.4% | +6.1% | +6.6% | +8.9% | +8.7% |
| EPS (₹) | 3.51 | 5.84 | 5.04 | 3.57 | 28.40 | 29.02 | 21.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 19.34 | 17.85 | 17.85 | 17.85 | 3.76 | 3.76 | 3.01 |
| Reserves & surplus | 84.88 | 70.19 | 60.66 | 52.55 | 27.27 | 16.56 | 6.40 |
| Shareholders' funds (net worth) | 104 | 88.04 | 78.51 | 70.40 | 31.03 | 20.32 | 9.41 |
| Secured loans | 85.45 | 71.79 | 0.00 | 25.52 | 31.38 | 18.05 | 8.99 |
| Unsecured loans | 5.47 | 5.46 | 2.37 | 0.00 | 0.59 | 1.55 | 2.61 |
| Total debt | 90.92 | 77.25 | 2.37 | 25.52 | 31.97 | 19.60 | 11.60 |
| Total liabilities | 196 | 166 | 113 | 96.01 | 63.01 | 39.93 | 21.01 |
| Assets | |||||||
| Gross block | 37.90 | 32.07 | 30.03 | 28.37 | 9.91 | 11.30 | 3.63 |
| Net block | 24.65 | 22.33 | 23.58 | 25.36 | 7.97 | 10.17 | 3.24 |
| Capital work in progress | 2.64 | 2.93 | 2.06 | 1.15 | 0.00 | 0.00 | 0.00 |
| Investments | 63.09 | 48.33 | 2.11 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 45.92 | 39.28 | 37.58 | 29.93 | 24.25 | 20.31 | 15.69 |
| Sundry debtors | 59.17 | 53.82 | 41.39 | 39.04 | 42.04 | 22.98 | 11.21 |
| Cash & bank balances | 0.11 | 0.39 | 0.31 | 2.37 | 2.16 | 1.38 | 0.66 |
| Loans & advances | 22.19 | 17.99 | 24.39 | 15.59 | 5.62 | 5.12 | 2.49 |
| Total current assets | 127 | 111 | 104 | 86.93 | 74.07 | 49.79 | 30.05 |
| Total current liabilities | 24.24 | 23.40 | 21.79 | 21.33 | 19.22 | 20.39 | 12.47 |
| Net working capital | 103 | 88.08 | 81.88 | 65.60 | 54.85 | 29.40 | 17.58 |
| Total assets | 196 | 166 | 113 | 96.01 | 63.01 | 39.93 | 21.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.38 | 0.31 | 1.27 | 2.16 | 1.38 | 0.66 | 0.14 |
| Net cash from operating activities | 18.77 | 26.09 | 1.36 | (7.54) | (1.72) | 1.88 | 4.18 |
| Net cash from investing activities | (18.27) | (48.90) | (1.78) | (25.10) | 2.37 | (7.84) | (3.66) |
| Net cash from financing activities | (0.78) | 22.88 | (1.07) | 31.74 | 0.13 | 6.69 | 0.00 |
| Net change in cash | (0.28) | 0.07 | (1.48) | (0.90) | 0.78 | 0.73 | 0.52 |
| Closing cash | 0.11 | 0.39 | 0.31 | 2.37 | 2.16 | 1.38 | 0.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +5.1% | +18.6% | +17.4% | -28.9% | +19.9% | +67.8% | - |
| EBITDA growth | -9.6% | +27.2% | +61.9% | -31.9% | -2.1% | +77.0% | - |
| PBT growth | -34.5% | +17.9% | +40.4% | -39.8% | -3.0% | +70.9% | +99.1% |
| Net income growth | -36.8% | +15.8% | +41.1% | -34.2% | -11.2% | +72.6% | - |
| Revenue CAGR (3Y) | +13.5% | -0.3% | +0.0% | +12.7% | +41.3% | +1051.1% | - |
| EBITDA CAGR (3Y) | +21.9% | +11.9% | +2.6% | +5.7% | +52.9% | +1093.3% | - |
| Profitability & leverage | |||||||
| Net income margin | +4.4% | +7.2% | +7.4% | +6.1% | +7.3% | +8.9% | +8.7% |
| Return on capital employed | +9.6% | +14.6% | +14.7% | +13.8% | +32.8% | +53.6% | +64.8% |
| Return on net worth | +7.0% | +12.5% | +12.1% | +12.6% | +41.6% | +73.5% | +101.2% |
| Debt / equity | 0.87 | 0.48 | 0.19 | 0.57 | 1.00 | 1.05 | 1.29 |
| Long-term debt / equity | 0.26 | 0.17 | 0.03 | 0.03 | 0.04 | 0.00 | 0.00 |
| Interest cover | 46.44 | 29.92 | 21.01 | 22.32 | 15.76 | 8.68 | 6.06 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 4.35 | 4.67 | 4.18 | 5.44 | 13.80 | 16.35 | 38.49 |
| Inventory turnover | 3.58 | 3.77 | 3.62 | 3.84 | 6.57 | 6.78 | 5.90 |
| Debtors turnover | 2.70 | 3.04 | 3.04 | 2.57 | 4.50 | 7.14 | 7.57 |
| EPS (₹) | 3.46 | 5.84 | 5.04 | 3.57 | 28.40 | 29.02 | 21.00 |
| Dividend per share (₹) | 0.50 | 0.50 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 53.89 | 49.32 | 43.99 | 39.44 | 82.48 | 54.02 | 31.25 |
Investments & Acquisitions by QMS MAS
QMS MAS has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Saarathi Healthcare.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Disease management services are provided to patients in India. | saarathihealthcare.com | Thane, India | 2008 | Feb 2024 | $53.88M |
Complete acquisition details for QMS MAS
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of QMS MAS
3 dated milestones of QMS MAS across 30 years, from founding to its latest funding, stage changes and deals.
- Founded QMS MAS is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Saarathi Healthcare.
Web traffic of QMS MAS
The website of QMS MAS (qmsmas.com) receives about 1.9K visits a month.
- Monthly visits1.9K
▼ 78.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Qms Mas
Complete news archive for QMS MAS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QMS MAS
QMS MAS was founded in 1994.
QMS MAS is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
QMS MAS has 83 employees.
The primary company behind QMS MAS, Qms Medical Allied Services Limited, reported revenue of ₹174 Cr for FY 2026, up 11% year on year.
QMS MAS was founded in 1994 and is located in Mumbai, India. Digital marketing and scientific solution services are offered by the company to manufacturers in the medical devices sector. Operations are centered on supporting these clients with specialized tools and strategies for market outreach and technical compliance. The focus remains on the healthcare industry, with services tailored to regional and global needs in device production.
Yes, QMS MAS is publicly traded on NSE under the ticker symbol QMSMEDI.
QMS MAS has made 1 acquisition, including Saarathi Healthcare.
QMS MAS operates through Qms Medical Allied Services Limited.
The legal entities of QMS MAS currently have 8 directors, including Prajwal Jayasheela Poojari, Niken Ravin Shah, Mahesh Pahalraj Makhija and others.
